



Clinical trial results:

Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor

Summary

EudraCT number	2017-003432-37
Trial protocol	AT
Global end of trial date	05 July 2019

Results information

Result version number	v2 (current)
This version publication date	21 November 2020
First version publication date	19 July 2020
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	A005D-E01-201
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03724253
WHO universal trial number (UTN)	-
Other trial identifiers	CAAA503A12201: Novartis

Notes:

Sponsors

Sponsor organisation name	Advanced Accelerator Applications SA
Sponsor organisation address	20, rue Diesel, Saint-Genis Pouilly, France, 01630
Public contact	Novartis Clinical Disclosure Office, Advanced Accelerator Applications SA, 41 613241111, Novartis.email@novartis.com
Scientific contact	Novartis Clinical Disclosure Office, Advanced Accelerator Applications SA, 41 613241111, Novartis.email@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 July 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 July 2019
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to characterize preliminary targeting properties of [68Ga]-NeoBOMB1 in patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor (GRPR).

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.novfor> complete trial results.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 July 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 8
Country: Number of subjects enrolled	France: 11
Worldwide total number of subjects	19
EEA total number of subjects	19

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	10
From 65 to 84 years	9
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 3 centers in 2 countries: Austria (1) and France (2).

Pre-assignment

Screening details:

A total of 50 subjects were planned for the study (10 subjects for the dosimetry group and 40 subjects for the non dosimetry group). In total, 22 subjects were screened for eligibility and 19 subjects were enrolled (2 subjects in the dosimetry group and 17 subjects in the non dosimetry group).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Breast

Arm description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm type	Experimental
Investigational medicinal product name	[68Ga]-NeoBOMB1
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Kit for radiopharmaceutical preparation
Routes of administration	Intravenous use

Dosage and administration details:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm title	Prostate
------------------	----------

Arm description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm type	Experimental
Investigational medicinal product name	[68Ga]-NeoBOMB1
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Kit for radiopharmaceutical preparation
Routes of administration	Intravenous use

Dosage and administration details:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm title	Colorectal
------------------	------------

Arm description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm type	Experimental
Investigational medicinal product name	[68Ga]-NeoBOMB1
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Kit for radiopharmaceutical preparation
Routes of administration	Intravenous use

Dosage and administration details:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm title	Non-Small Cell Lung Cancer (NSCLC)
------------------	------------------------------------

Arm description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm type	Experimental
Investigational medicinal product name	[68Ga]-NeoBOMB1
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Kit for radiopharmaceutical preparation
Routes of administration	Intravenous use

Dosage and administration details:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm title	Small-Cell Lung Cancer (SCLC)
------------------	-------------------------------

Arm description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Arm type	Experimental
Investigational medicinal product name	[68Ga]-NeoBOMB1
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Kit for radiopharmaceutical preparation
Routes of administration	Intravenous use

Dosage and administration details:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Number of subjects in period 1	Breast	Prostate	Colorectal
Started	5	5	5
Completed	5	5	5

Number of subjects in period 1	Non-Small Cell Lung Cancer (NSCLC)	Small-Cell Lung Cancer (SCLC)
Started	3	1
Completed	3	1

Baseline characteristics

Reporting groups

Reporting group title	Breast
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Prostate
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Colorectal
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Non-Small Cell Lung Cancer (NSCLC)
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Small-Cell Lung Cancer (SCLC)
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	

Reporting group values	Breast	Prostate	Colorectal
Number of subjects	5	5	5
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	2	3
From 65-84 years	2	3	2
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	61.8	65.4	64.2
standard deviation	± 7.60	± 6.31	± 13.68
Sex: Female, Male Units: Participants			
Female	5	0	1
Male	0	5	4

Race/Ethnicity, Customized			
Units: Subjects			
White	0	2	3
Not Collected	5	3	2
Diagnostic Stage			
The overall diagnostic stage uses the stage at screening visit and the Tumour, Node, Metastasis (TNM) staging uses the latest available stage. Stage III indicates a locally advanced cancer that is likely to grow and spread; stage IIIA = the cancer has spread into nearby tissues; stage IIIC = the cancer cells across the tumor are poorly differentiated, meaning they look very different from healthy cells. Stage IV means that the cancer has spread to distant parts of the body and may be called advanced or metastatic cancer.			
Units: Subjects			
Stage IIIA	0	1	0
Stage IIIC	0	0	0
Stage IV	5	4	5
Baseline Weight			
Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.			
Units: kilogram (kg)			
arithmetic mean	70.6	85.2	72.6
standard deviation	± 10.53	± 7.46	± 8.63
Baseline Height			
Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.			
Units: centimeter (cm)			
arithmetic mean	165.6	175.4	170.4
standard deviation	± 3.21	± 5.94	± 6.23
Baseline Body Mass Index			
Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.			
Units: kilogram per square metre (kg/m ²)			
arithmetic mean	25.84	27.79	24.90
standard deviation	± 4.563	± 3.202	± 1.514
Time from Initial Diagnosis of Primary Disease			
Time from initial diagnosis (months) is calculated as (date of IMP administration - date of initial diagnosis + 1)/30.4375.			
Units: Months			
arithmetic mean	117.3	50.5	24.3
standard deviation	± 64.61	± 74.48	± 25.40

Reporting group values	Non-Small Cell Lung Cancer (NSCLC)	Small-Cell Lung Cancer (SCLC)	Total
Number of subjects	3	1	19
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	1	1	10

From 65-84 years	2	0	9
85 years and over	0	0	0

Age Continuous Units: Years arithmetic mean standard deviation	64.7 ± 3.21	54.0 ± 999	-
Sex: Female, Male Units: Participants			
Female	1	1	8
Male	2	0	11
Race/Ethnicity, Customized Units: Subjects			
White	2	1	8
Not Collected	1	0	11
Diagnostic Stage			
The overall diagnostic stage uses the stage at screening visit and the Tumour, Node, Metastasis (TNM) staging uses the latest available stage. Stage III indicates a locally advanced cancer that is likely to grow and spread; stage IIIA = the cancer has spread into nearby tissues; stage IIIC = the cancer cells across the tumor are poorly differentiated, meaning they look very different from healthy cells. Stage IV means that the cancer has spread to distant parts of the body and may be called advanced or metastatic cancer.			
Units: Subjects			
Stage IIIA	1	0	2
Stage IIIC	1	0	1
Stage IV	1	1	16
Baseline Weight			
Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.			
Units: kilogram (kg) arithmetic mean standard deviation	72.1 ± 23.38	62.8 ± 999	-
Baseline Height			
Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.			
Units: centimeter (cm) arithmetic mean standard deviation	165.7 ± 3.51	168.0 ± 999	-
Baseline Body Mass Index			
Baseline is defined as the last measurement prior to Investigational Medicinal Product (IMP) administration.			
Units: kilogram per square metre (kg/m ²) arithmetic mean standard deviation	26.04 ± 7.552	22.25 ± 999	-
Time from Initial Diagnosis of Primary Disease			
Time from initial diagnosis (months) is calculated as (date of IMP administration - date of initial diagnosis + 1)/30.4375.			
Units: Months arithmetic mean standard deviation	1.6 ± 1.46	1.1 ± 999	-

End points

End points reporting groups

Reporting group title	Breast
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Prostate
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Colorectal
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Non-Small Cell Lung Cancer (NSCLC)
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	
Reporting group title	Small-Cell Lung Cancer (SCLC)
Reporting group description: All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].	

Primary: Number of lesions detected by [68Ga]-NeoBOMB1

End point title	Number of lesions detected by [68Ga]-NeoBOMB1 ^[1]
End point description: The preliminary targeting properties of [68Ga]-NeoBOMB1 were to be assessed by summarizing the number of lesions identified by Positron Emission Tomography (PET) overall and split by GRPR positive and negative patients, as well as by tumor type. Only descriptive analysis performed.	
End point type	Primary
End point timeframe: [68Ga]-NeoBOMB1 PET imaging acquired at Day 1	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Lesion				
arithmetic mean (standard deviation)	17.0 (± 15.57)	2.2 (± 1.64)	6.0 (± 4.58)	3.3 (± 2.31)

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Lesion				
arithmetic mean (standard deviation)	1.0 (± 999)			

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants with Lesions detected by [68Ga]-NeoBOMB1 per Location

End point title	Number of Participants with Lesions detected by [68Ga]-NeoBOMB1 per Location ^[2]
-----------------	---

End point description:

The preliminary targeting properties of [68Ga]-NeoBOMB1 were to be assessed by summarizing the location of lesions identified by PET overall and split by GRPR positive and negative patients, as well as by tumor type. Only descriptive analysis performed.

End point type	Primary
----------------	---------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	3	3
Units: Participants				
Overall	5	5	3	3
Nodal	2	1	2	3
Skeletal	4	2	0	0
Skin/Superficial	2	0	0	0
Soft Tissue/Visceral	4	4	2	3

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Participants				

Overall	1			
Nodal	0			
Skeletal	0			
Skin/Superficial	0			
Soft Tissue/Visceral	1			

Statistical analyses

No statistical analyses for this end point

Primary: Non-Dosimetry Group: Standard Uptake Value (SUV) mean by timepoint and lesion location

End point title	Non-Dosimetry Group: Standard Uptake Value (SUV) mean by timepoint and lesion location ^[3]
-----------------	---

End point description:

Targeting properties of [68Ga]-NeoBOMB1 were to be evaluated by semi-quantitatively assessing radiotracer uptake at lesion level, identified via PET Imaging. The SUVmean and SUVmax (g/mL) of each lesion were to be calculated and reported by lesion location with summary statistics at all imaging time points. SUV was to be calculated overall and split by GRPR positive and negative patients, as well as by tumor type. Only descriptive analysis performed.

End point type	Primary
----------------	---------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1 (0.05 (only applicable for the Prostate Group), 1.50 and 2.50 hours)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Standard Uptake Value (SUV)				
arithmetic mean (standard deviation)				
SUV mean:Overall (0.05 hours)	999 (± 999)	1.634 (± 0.8221)	999 (± 999)	999 (± 999)
SUV mean:Nodal (0.05 hours)	999 (± 999)	0.630 (± 999)	999 (± 999)	999 (± 999)
SUV mean:Skeletal (0.05 hours)	999 (± 999)	1.890 (± 999)	999 (± 999)	999 (± 999)
SUV mean:Skin/Superficial (0.05 hours)	999 (± 999)	999 (± 999)	999 (± 999)	999 (± 999)
SUV mean:Soft Tissue/Visceral (0.05 hours)	999 (± 999)	1.558 (± 0.9517)	999 (± 999)	999 (± 999)
SUV mean:Overall (1.50 hours)	6.833 (± 5.0645)	11.638 (± 15.9172)	2.582 (± 0.8142)	1.560 (± 0.4468)
SUV mean:Nodal (1.50 hours)	4.720 (± 5.4447)	1.080 (± 0.2263)	1.700 (± 0.3960)	1.560 (± 0.4468)
SUV mean:Skeletal (1.50 hours)	3.670 (± 4.0164)	1.470 (± 0.7778)	999 (± 999)	999 (± 999)
SUV mean:Skin/Superficial (1.50 hours)	4.370 (± 999)	999 (± 999)	0.560 (± 999)	999 (± 999)
SUV mean:Soft Tissue/Visceral (1.50 hours)	6.833 (± 5.0645)	14.043 (± 17.2993)	2.582 (± 0.8142)	1.427 (± 0.4274)
SUV mean:Overall (2.50 hours)	6.903 (± 5.4174)	9.088 (± 10.7319)	2.258 (± 0.9105)	1.273 (± 0.2386)

SUV mean:Nodal (2.50 hours)	4.900 (± 6.0528)	0.800 (± 0.2687)	2.715 (± 1.5344)	1.273 (± 0.2386)
SUV mean:Skeletal (2.50 hours)	3.685 (± 4.4336)	1.455 (± 0.8415)	999 (± 999)	999 (± 999)
SUV mean:Skin/Superficial (2.50 hours)	4.360 (± 999)	999 (± 999)	0.450 (± 999)	999 (± 999)
SUV mean:Soft Tissue/Visceral (2.50 hours)	6.903 (± 5.4174)	10.848 (± 11.5294)	2.060 (± 0.5115)	1.193 (± 0.3250)

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Standard Uptake Value (SUV)				
arithmetic mean (standard deviation)				
SUV mean:Overall (0.05 hours)	999 (± 999)			
SUV mean:Nodal (0.05 hours)	999 (± 999)			
SUV mean:Skeletal (0.05 hours)	999 (± 999)			
SUV mean:Skin/Superficial (0.05 hours)	999 (± 999)			
SUV mean:Soft Tissue/Visceral (0.05 hours)	999 (± 999)			
SUV mean:Overall (1.50 hours)	1.250 (± 999)			
SUV mean:Nodal (1.50 hours)	1.250 (± 999)			
SUV mean:Skeletal (1.50 hours)	999 (± 999)			
SUV mean:Skin/Superficial (1.50 hours)	999 (± 999)			
SUV mean:Soft Tissue/Visceral (1.50 hours)	1.150 (± 999)			
SUV mean:Overall (2.50 hours)	0.850 (± 999)			
SUV mean:Nodal (2.50 hours)	0.850 (± 999)			
SUV mean:Skeletal (2.50 hours)	999 (± 999)			
SUV mean:Skin/Superficial (2.50 hours)	999 (± 999)			
SUV mean:Soft Tissue/Visceral (2.50 hours)	0.710 (± 999)			

Statistical analyses

No statistical analyses for this end point

Primary: Non-Dosimetry Group: Standard Uptake Value (SUV) max by timepoint and lesion location

End point title	Non-Dosimetry Group: Standard Uptake Value (SUV) max by timepoint and lesion location ^[4]
-----------------	--

End point description:

Targeting properties of [68Ga]-NeoBOMB1 were to be evaluated by semi-quantitatively assessing radiotracer uptake at lesion level, identified via PET Imaging. The SUVmean and SUVmax (g/mL) of each lesion were to be calculated and reported by lesion location with summary statistics at all imaging time points. SUV was to be calculated overall and split by GRPR positive and negative patients, as well as by tumor type. Only descriptive analysis performed.

End point type	Primary
----------------	---------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1 (0.05 (only applicable for the Prostate Group), 1.50

and 2.50 hours)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Standard Uptake Value (SUV)				
arithmetic mean (standard deviation)				
SUV max:Overall (0.05 hours)	999 (± 999)	2.166 (± 1.1164)	999 (± 999)	999 (± 999)
SUV max:Nodal (0.05 hours)	999 (± 999)	0.880 (± 999)	999 (± 999)	999 (± 999)
SUV max:Skeletal (0.05 hours)	999 (± 999)	2.480 (± 999)	999 (± 999)	999 (± 999)
SUV max:Skin/Superficial (0.05 hours)	999 (± 999)	999 (± 999)	999 (± 999)	999 (± 999)
SUV max:Soft Tissue/Visceral (0.05 hours)	999 (± 999)	2.088 (± 1.2731)	999 (± 999)	999 (± 999)
SUV max:Overall (1.50 hours)	19.040 (± 17.5106)	17.326 (± 24.2165)	3.570 (± 0.7504)	2.097 (± 0.6863)
SUV max:Nodal (1.50 hours)	9.070 (± 11.3986)	1.505 (± 0.4313)	2.090 (± 0.5233)	1.917 (± 0.7139)
SUV max:Skeletal (1.50 hours)	10.325 (± 13.0461)	2.135 (± 0.9687)	999 (± 999)	999 (± 999)
SUV max:Skin/Superficial (1.50 hours)	7.400 (± 999)	999 (± 999)	0.750 (± 999)	999 (± 999)
SUV max:Soft Tissue/Visceral (1.50 hours)	18.580 (± 17.5086)	20.953 (± 26.3485)	3.570 (± 0.7504)	2.097 (± 0.6863)
SUV max:Overall (2.50 hours)	23.120 (± 19.7908)	14.544 (± 18.4921)	2.890 (± 0.5866)	2.050 (± 0.8314)
SUV max:Nodal (2.50 hours)	10.440 (± 13.8169)	1.305 (± 0.3323)	2.870 (± 1.3859)	1.783 (± 0.6676)
SUV max:Skeletal (2.50 hours)	15.475 (± 20.9091)	2.115 (± 1.0677)	999 (± 999)	999 (± 999)
SUV max:Skin/Superficial (2.50 hours)	7.950 (± 999)	999 (± 999)	0.600 (± 999)	999 (± 999)
SUV max:Soft Tissue/Visceral (2.50 hours)	22.140 (± 19.3278)	17.463 (± 19.9790)	2.890 (± 0.5866)	2.000 (± 0.8982)

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Standard Uptake Value (SUV)				
arithmetic mean (standard deviation)				
SUV max:Overall (0.05 hours)	999 (± 999)			
SUV max:Nodal (0.05 hours)	999 (± 999)			
SUV max:Skeletal (0.05 hours)	999 (± 999)			
SUV max:Skin/Superficial (0.05 hours)	999 (± 999)			
SUV max:Soft Tissue/Visceral (0.05 hours)	999 (± 999)			
SUV max:Overall (1.50 hours)	1.810 (± 999)			
SUV max:Nodal (1.50 hours)	1.450 (± 999)			

SUV max:Skeletal (1.50 hours)	999 (± 999)			
SUV max:Skin/Superficial (1.50 hours)	999 (± 999)			
SUV max:Soft Tissue/Visceral (1.50 hours)	1.810 (± 999)			
SUV max:Overall (2.50 hours)	1.390 (± 999)			
SUV max:Nodal (2.50 hours)	1.180 (± 999)			
SUV max:Skeletal (2.50 hours)	999 (± 999)			
SUV max:Skin/Superficial (2.50 hours)	999 (± 999)			
SUV max:Soft Tissue/Visceral (2.50 hours)	1.390 (± 999)			

Statistical analyses

No statistical analyses for this end point

Primary: Dosimetry Group: Standard Uptake Value (SUV) mean by timepoint and lesion location

End point title	Dosimetry Group: Standard Uptake Value (SUV) mean by timepoint and lesion location ^{[5][6]}
-----------------	--

End point description:

Targeting properties of [68Ga]-NeoBOMB1 were to be evaluated by semi-quantitatively assessing radiotracer uptake at lesion level, identified via PET Imaging. The SUVmean and SUVmax (g/mL) of each lesion were to be calculated and reported by lesion location with summary statistics at all imaging time points. SUV was to be calculated overall and split by GRPR positive and negative patients, as well as by tumor type. Only descriptive analysis performed.

End point type	Primary
----------------	---------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1 (0.15, 1.00, 2.00 and 4.00 hours)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: Standard Uptake Value (SUV)				
arithmetic mean (standard deviation)				
SUV mean:Overall (0.15 hours)	5.615 (± 5.1265)			
SUV mean:Nodal (0.15 hours)	2.565 (± 1.0394)			
SUV mean:Skeletal (0.15 hours)	2.140 (± 0.2121)			
SUV mean:Skin/Superficial (0.15 hours)	1.250 (± 999)			
SUV mean:Soft Tissue/Visceral (0.15 hours)	9.240 (± 999)			
SUV mean:Overall (1.00 hours)	4.840 (± 5.1336)			

SUV mean:Nodal (1.00 hours)	2.035 (± 1.1667)			
SUV mean:Skeletal (1.00 hours)	1.935 (± 1.2233)			
SUV mean:Skin/Superficial (1.00 hours)	1.520 (± 999)			
SUV mean:Soft Tissue/Visceral (1.00 hours)	8.470 (± 999)			
SUV mean:Overall (2.00 hours)	4.935 (± 5.4659)			
SUV mean:Nodal (2.00 hours)	1.865 (± 1.1667)			
SUV mean:Skeletal (2.00 hours)	1.635 (± 0.7990)			
SUV mean:Skin/Superficial (2.00 hours)	1.650 (± 999)			
SUV mean:Soft Tissue/Visceral (2.00 hours)	8.800 (± 999)			
SUV mean:Overall (4.00 hours)	5.105 (± 5.7064)			
SUV mean:Nodal (4.00 hours)	1.475 (± 1.0819)			
SUV mean:Skeletal (4.00 hours)	1.930 (± 1.2162)			
SUV mean:Skin/Superficial (4.00 hours)	1.100 (± 999)			
SUV mean:Soft Tissue/Visceral (4.00 hours)	9.140 (± 999)			

Statistical analyses

No statistical analyses for this end point

Primary: Dosimetry Group: Standard Uptake Value (SUV) max by timepoint and lesion location

End point title	Dosimetry Group: Standard Uptake Value (SUV) max by timepoint and lesion location ^[7] ^[8]
-----------------	---

End point description:

Targeting properties of [68Ga]-NeoBOMB1 were to be evaluated by semi-quantitatively assessing radiotracer uptake at lesion level, identified via PET Imaging. The SUVmean and SUVmax (g/mL) of each lesion were to be calculated and reported by lesion location with summary statistics at all imaging time points. SUV was to be calculated overall and split by GRPR positive and negative patients, as well as by tumor type. Only descriptive analysis performed.

End point type	Primary
----------------	---------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1 (0.15, 1.00, 2.00 and 4.00 hours)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: Standard Uptake Value (SUV)				
arithmetic mean (standard deviation)				
SUV max:Overall(0.15 hours)	7.575 (± 6.7104)			
SUV max:Nodal (0.15 hours)	3.405 (± 0.8132)			
SUV max:Skeletal (0.15 hours)	2.740 (± 0.3111)			
SUV max:Skin/Superficial (0.15 hours)	1.450 (± 999)			
SUV max:Soft Tissue/Visceral (0.15 hours)	12.320 (± 999)			
SUV max:Overall (1.00 hours)	11.550 (± 13.7603)			
SUV max:Nodal (1.00 hours)	2.660 (± 1.1879)			
SUV max:Skeletal (1.00 hours)	2.595 (± 1.5203)			
SUV max:Skin/Superficial (1.00 hours)	1.750 (± 999)			
SUV max:Soft Tissue/Visceral (1.00 hours)	21.280 (± 999)			
SUV max:Overall (2.00 hours)	13.680 (± 17.1827)			
SUV max:Nodal (2.00 hours)	2.625 (± 1.5486)			
SUV max:Skeletal (2.00 hours)	2.445 (± 1.3081)			
SUV max:Skin/Superficial (2.00 hours)	2.080 (± 999)			
SUV max:Soft Tissue/Visceral (2.00 hours)	25.830 (± 999)			
SUV max:Overall (4.00 hours)	13.950 (± 17.5787)			
SUV max:Nodal (4.00 hours)	2.050 (± 1.3011)			
SUV max:Skeletal (4.00 hours)	3.205 (± 2.3829)			
SUV max:Skin/Superficial (4.00 hours)	1.640 (± 999)			
SUV max:Soft Tissue/Visceral (4.00 hours)	26.380 (± 999)			

Statistical analyses

No statistical analyses for this end point

Primary: Dosimetry Group: Evaluation of percentage of injected dose reaching the target (TACs) in tumors

End point title	Dosimetry Group: Evaluation of percentage of injected dose reaching the target (TACs) in tumors ^[9] ^[10]
End point description: For patients included in the dosimetry group, the percentage of injected dose per gram of tissue (%ID/g) reaching tumor lesions was to be calculated using the acquired PET images at each time point. The resulting TACs were to be summarized descriptively.	
End point type	Primary

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1 (0.15, 1.00, 2.00 and 4.00 hours)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: %ID/g				
number (not applicable)				
Participant 1: 15 min post-dose (T1 Chest)	0.00347			
Participant 1: 15 min post-dose (T2 Left rib)	0.00384			
Participant 1: 15 min post-dose (T3 Spine)	0.00469			
Participant 1: 1 hour post-dose (T1 Chest)	0.00218			
Participant 1: 1 hour post-dose (T2 Left rib)	0.00251			
Participant 1: 1 hour post-dose (T3 Spine)	0.00225			
Participant 1: 2 hours post-dose (T1 Chest)	0.00149			
Participant 1: 2 hours post-dose (T2 Left rib)	0.00173			
Participant 1: 2 hours post-dose (T3 Spine)	0.00185			
Participant 1: 4 hours post-dose (T1 Chest)	0.00129			
Participant 1: 4 hours post-dose (T2 Left rib)	0.00167			
Participant 1: 4 hours post-dose (T3 Spine)	0.00195			
Participant 2: 15 min post-dose (T1 lungL)	0.00367			
Participant 2: 15 min post-dose (T2 lungR)	0.00466			
Participant 2: 15 min post-dose (T3 liverL)	0.01353			
Participant 2: 15 min post-dose (T4 liverR1)	0.01304			
Participant 2: 15 min post-dose (T5 liverR2)	0.01504			
Participant 2: 15 min post-dose (T6 sacrumL)	0.00315			
Participant 2: 15 min post-dose (T7 liverP)	0.01218			
Participant 2: 15 min post-dose (T8 liverR)	0.01079			
Participant 2: 1 hour post-dose (T1 lungL)	0.00455			

Participant 2: 1 hour post-dose (T2 lungR)	0.00463			
Participant 2: 1 hour post-dose (T3 liverL)	0.01800			
Participant 2: 1 hour post-dose (T4 liverR1)	0.01400			
Participant 2: 1 hour post-dose (T5 liverR2)	0.01928			
Participant 2: 1 hour post-dose (T6 sacrumL)	0.00289			
Participant 2: 1 hour post-dose (T7 liverP)	0.01180			
Participant 2: 1 hour post-dose (T8 liverR)	0.00961			
Participant 2: 2 hours post-dose (T1 lungL)	0.00481			
Participant 2: 2 hours post-dose (T2 lungR)	0.00377			
Participant 2: 2 hours post-dose (T3 liverL)	0.00984			
Participant 2: 2 hours post-dose (T4 liverR1)	0.01527			
Participant 2: 2 hours post-dose (T5 liverR2)	0.02197			
Participant 2: 2 hours post-dose (T6 sacrumL)	0.00254			
Participant 2: 2 hours post-dose (T7 liverP)	0.01242			
Participant 2: 2 hours post-dose (T8 liverR)	0.01088			
Participant 2: 4 hours post-dose (T1 lungL)	0.00385			
Participant 2: 4 hours post-dose (T2 lungR)	0.00248			
Participant 2: 4 hours post-dose (T3 liverL)	0.01782			
Participant 2: 4 hours post-dose (T4 liverR1)	0.01164			
Participant 2: 4 hours post-dose (T5 liverR2)	0.02119			
Participant 2: 4 hours post-dose (T6 sacrumL)	0.00188			
Participant 2: 4 hours post-dose (T7 liverP)	0.01082			
Participant 2: 4 hours post-dose (T8 liverR)	0.01012			

Statistical analyses

No statistical analyses for this end point

Primary: Dosimetry Group: Evaluation of percentage of injected dose reaching the target (TACs) in organs

End point title	Dosimetry Group: Evaluation of percentage of injected dose reaching the target (TACs) in organs ^{[11][12]}
-----------------	---

End point description:

For patients included in the dosimetry group, the percentage of injected dose per gram of tissue (%ID/g) reaching source organs was to be calculated using the acquired PET images at each time point.

The resulting TACs were to be summarized descriptively.

End point type	Primary
End point timeframe:	
[68Ga]-NeoBOMB1 PET imaging acquired at Day 1 (0.15, 1.00, 2.00 and 4.00 hours)	

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis performed.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: %ID/g				
number (not applicable)				
Participant 1: 15 min post-dose (Bladder)	0.03132			
Participant 1: 15 min post-dose (Heart)	0.00600			
Participant 1: 15 min post-dose (Kidney)	0.00688			
Participant 1: 15 min post-dose (Liver)	0.00794			
Participant 1: 15 min post-dose (Lung)	0.00218			
Participant 1: 15 min post-dose (Marrow)	0.00331			
Participant 1: 15 min post-dose (Pancreas)	0.04711			
Participant 1: 15 min post-dose (Spleen)	0.00409			
Participant 1: 1 hour post-dose (Bladder)	0.04259			
Participant 1: 1 hour post-dose (Heart)	0.00241			
Participant 1: 1 hour post-dose (Kidney)	0.00577			
Participant 1: 1 hour post-dose (Liver)	0.00296			
Participant 1: 1 hour post-dose (Lung)	0.00095			
Participant 1: 1 hour post-dose (Marrow)	0.00116			
Participant 1: 1 hour post-dose (Pancreas)	0.04836			
Participant 1: 1 hour post-dose (Spleen)	0.00211			
Participant 1: 2 hours post-dose (Bladder)	0.02141			
Participant 1: 2 hours post-dose (Heart)	0.00163			
Participant 1: 2 hours post-dose (Kidney)	0.00239			
Participant 1: 2 hours post-dose (Liver)	0.00197			
Participant 1: 2 hours post-dose (Lung)	0.00068			
Participant 1: 2 hours post-dose (Marrow)	0.00092			
Participant 1: 2 hours post-dose (Pancreas)	0.05445			
Participant 1: 2 hours post-dose (Spleen)	0.00141			

Participant 1: 4 hours post-dose (Bladder)	0.01790			
Participant 1: 4 hours post-dose (Heart)	0.00130			
Participant 1: 4 hours post-dose (Kidney)	0.00149			
Participant 1: 4 hours post-dose (Liver)	0.00162			
Participant 1: 4 hours post-dose (Lung)	0.00062			
Participant 1: 4 hours post-dose (Marrow)	0.00035			
Participant 1: 4 hours post-dose (Pancreas)	0.06280			
Participant 1: 4 hours post-dose (Spleen)	0.00120			
Participant 2: 15 min post-dose (Bladder)	0.02682			
Participant 2: 15 min post-dose (Heart)	0.00340			
Participant 2: 15 min post-dose (Kidney)	0.00480			
Participant 2: 15 min post-dose (Liver)	0.00866			
Participant 2: 15 min post-dose (Lung)	0.00124			
Participant 2: 15 min post-dose (Marrow)	0.00186			
Participant 2: 15 min post-dose (Pancreas)	0.02146			
Participant 2: 15 min post-dose (Spleen)	0.00338			
Participant 2: 1 hour post-dose (Bladder)	0.06480			
Participant 2: 1 hour post-dose (Heart)	0.00207			
Participant 2: 1 hour post-dose (Kidney)	0.00380			
Participant 2: 1 hour post-dose (Liver)	0.00564			
Participant 2: 1 hour post-dose (Lung)	0.00088			
Participant 2: 1 hour post-dose (Marrow)	0.00136			
Participant 2: 1 hour post-dose (Pancreas)	0.02909			
Participant 2: 1 hour post-dose (Spleen)	0.00256			
Participant 2: 2 hours post-dose (Bladder)	0.04055			
Participant 2: 2 hours post-dose (Heart)	0.00142			
Participant 2: 2 hours post-dose (Kidney)	0.00505			
Participant 2: 2 hours post-dose (Liver)	0.00428			
Participant 2: 2 hours post-dose (Lung)	0.00059			
Participant 2: 2 hours post-dose (Marrow)	0.00100			
Participant 2: 2 hours post-dose (Pancreas)	0.03450			
Participant 2: 2 hours post-dose (Spleen)	0.00191			
Participant 2: 4 hours post-dose (Bladder)	0.11045			
Participant 2: 4 hours post-dose (Heart)	0.00093			
Participant 2: 4 hours post-dose (Kidney)	0.00278			
Participant 2: 4 hours post-dose (Liver)	0.00317			
Participant 2: 4 hours post-dose (Lung)	0.00039			
Participant 2: 4 hours post-dose (Marrow)	0.00072			

Participant 2: 4 hours post-dose (Pancreas)	0.03745			
Participant 2: 4 hours post-dose (Spleen)	0.00145			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Emergent Adverse Events profile

End point title	Treatment Emergent Adverse Events profile
-----------------	---

End point description:

Treatment-emergent adverse events (TEAEs) were collected from first dosing (single administration, Day 1) up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the patient was lost to follow-up or withdrew consent. The distribution of adverse events was done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Grade 3/4/5 TEAEs, Serious Adverse Event TEAEs, Interruption of [68Ga]-NeoBOMB1 Due to Any TEAEs and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dosing (single administration, Day 1) up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the patient was lost to follow-up or withdrew consent.

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Participants				
Treatment-Emergent Adverse Events (TEAEs)	0	1	3	3
IMP-Related TEAEs	0	0	0	0
Grade 3/4/5 TEAEs	0	0	0	0
IMP-Related Grade 3/4/5 TEAEs	0	0	0	0
Serious TEAEs	0	0	0	0
IMP-Related Serious TEAEs	0	0	0	0
TEAEs Interruption of [68Ga]-NeoBOMB1	0	0	0	0
IMP-Related TEAEs Interruption of [68Ga]-NeoBOMB1	0	0	0	0
Deaths Due to AEs	0	0	0	0

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			

Units: Participants				
Treatment-Emergent Adverse Events (TEAEs)	1			
IMP-Related TEAEs	0			
Grade 3/4/5 TEAEs	1			
IMP-Related Grade 3/4/5 TEAEs	0			
Serious TEAEs	1			
IMP-Related Serious TEAEs	0			
TEAEs Interruption of [68Ga]-NeoBOMB1	0			
IMP-Related TEAEs Interruption of [68Ga]-NeoBOMB1	0			
Deaths Due to AEs	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of lesions detected by Conventional Imaging

End point title	Number of lesions detected by Conventional Imaging
End point description:	
The preliminary targeting properties of [68Ga]-NeoBOMB1 were to be assessed by summarizing the number of lesions identified by Positron Emission Tomography (PET) overall and split by GRPR positive and negative patients, as well as by tumor type. The number of lesions identified by aforementioned PET imaging were to be compared with the number of lesions identified by the comparable conventional imaging. Only descriptive analysis performed.	
End point type	Secondary
End point timeframe:	
Conventional imaging collected within 3 months prior to study entry up to [68Ga]-NeoBOMB1 PET imaging acquired at Day 1	

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Lesion				
arithmetic mean (standard deviation)	18.4 (± 15.81)	13.8 (± 21.51)	12.2 (± 9.86)	10.0 (± 7.55)

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Lesion				
arithmetic mean (standard deviation)	2.0 (± 999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Lesions detected by Conventional imaging per Location

End point title	Number of Participants with Lesions detected by Conventional imaging per Location
-----------------	---

End point description:

The preliminary targeting properties of [68Ga]-NeoBOMB1 were to be assessed by summarizing the location of lesions identified by PET overall and split by GRPR positive and negative patients, as well as by tumor type. The location of lesions identified by aforementioned PET imaging were to be compared with the location of lesions identified by the comparable conventional imaging. Only descriptive analysis performed.

End point type	Secondary
----------------	-----------

End point timeframe:

Conventional imaging collected within 3 months prior to study entry up to [68Ga]-NeoBOMB1 PET imaging acquired at Day 1

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Participants				
Overall	5	5	5	3
Nodal	4	1	2	3
Skeletal	4	2	0	0
Skin/Superficial	2	0	1	0
Soft Tissue/Visceral	4	4	5	3

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Participants				
Overall	1			
Nodal	1			
Skeletal	0			
Skin/Superficial	0			
Soft Tissue/Visceral	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Lesion-level analyses of diagnostics by [68Ga]-NeoBOMB1 compared with conventional imaging

End point title	Lesion-level analyses of diagnostics by [68Ga]-NeoBOMB1 compared with conventional imaging
-----------------	--

End point description:

At lesion level, overall, positive, and negative agreement of [68Ga]-NeoBOMB1 were to be calculated based on the aforementioned tabulations as follows:

- Overall agreement = $100\% \times (\text{Double positive} + \text{Double negative}) / \text{total number of lesions identified by either imaging procedures}$
- Positive agreement = $100\% \times \text{Double positive} / (\text{Double positive} + \text{Comparator single positive})$
- Negative agreement = $100\% \times \text{Double negative} / (\text{Double negative} + \text{Comparator single negative})$.

End point type	Secondary
----------------	-----------

End point timeframe:

Conventional imaging collected within 3 months prior to study entry up to [68Ga]-NeoBOMB1 PET imaging acquired at Day 1

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Percent agreement				
number (confidence interval 95%)				
Overall (Positive Agreement)	52.2 (41.5 to 62.7)	14.5 (7.2 to 25.0)	29.5 (18.5 to 42.6)	33.3 (17.3 to 52.8)
Overall (Overall Agreement)	37.2 (28.9 to 46.2)	14.3 (7.1 to 24.7)	29.5 (18.5 to 42.6)	33.3 (17.3 to 52.8)
Nodal (Positive Agreement)	64.3 (35.1 to 87.2)	0.0 (0.0 to 30.8)	66.7 (9.4 to 99.2)	26.9 (11.6 to 47.8)
Nodal (Overall agreement)	64.3 (35.1 to 87.2)	0.0 (0.0 to 28.5)	66.7 (9.4 to 99.2)	26.9 (11.6 to 47.8)
Skeletal (Positive Agreement)	22.9 (12.0 to 37.3)	11.1 (4.2 to 22.6)	999 (999 to 999)	999 (999 to 999)
Skeletal (Overall agreement)	18.3 (9.5 to 30.4)	11.1 (4.2 to 22.6)	999 (999 to 999)	999 (999 to 999)
Skin/Superficial (Positive Agreement)	100.0 (15.8 to 100.0)	999 (999 to 999)	0.0 (0.0 to 97.5)	999 (999 to 999)
Skin/Superficial (Overall agreement)	100.0 (15.8 to 100.0)	999 (999 to 999)	0.0 (0.0 to 97.5)	999 (999 to 999)
Soft Tissue/Visceral (Positive Agreement)	92.9 (76.5 to 99.1)	80.0 (28.4 to 99.5)	28.1 (17.0 to 41.5)	75.0 (19.4 to 99.4)
Soft Tissue/Visceral (Overall agreement)	49.1 (35.1 to 63.2)	80.0 (28.4 to 99.5)	28.1 (17.0 to 41.5)	75.0 (19.4 to 99.4)

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Percent agreement				
number (confidence interval 95%)				
Overall (Positive Agreement)	50.0 (1.3 to 98.7)			
Overall (Overall Agreement)	50.0 (1.3 to 98.7)			
Nodal (Positive Agreement)	0.0 (0.0 to 97.5)			
Nodal (Overall agreement)	0.0 (0.0 to 97.5)			
Skeletal (Positive Agreement)	999 (999 to 999)			
Skeletal (Overall agreement)	999 (999 to 999)			
Skin/Superficial (Positive Agreement)	999 (999 to 999)			
Skin/Superficial (Overall agreement)	999 (999 to 999)			
Soft Tissue/Visceral (Positive Agreement)	100.0 (2.5 to 100.0)			
Soft Tissue/Visceral (Overall agreement)	100.0 (2.5 to 100.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Patient-level analyses of diagnostics by [68Ga]-NeoBOMB1 compared with conventional imaging

End point title	Patient-level analyses of diagnostics by [68Ga]-NeoBOMB1 compared with conventional imaging
-----------------	---

End point description:

At patient level, positive agreement was defined as the proportion of subjects with at least one lesion detected by conventional imaging in the specified location that also have at least one lesion detected by [68Ga]-NeoBOMB1. Overall agreement was defined as the proportion of subjects with at least one lesion detected in either imaging in the specified location that also have at least one lesion detected by [68Ga]-NeoBOMB1.

End point type	Secondary
----------------	-----------

End point timeframe:

Conventional imaging collected within 3 months prior to study entry up to [68Ga]-NeoBOMB1 PET imaging acquired at Day 1

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Percent agreement				
number (confidence interval 95%)				
Overall (Positive Agreement)	100.0 (47.8 to 100.0)	100.0 (47.8 to 100.0)	60.0 (14.7 to 94.7)	100.0 (29.2 to 100.0)
Overall (Overall Agreement)	100.0 (47.8 to 100.0)	100.0 (47.8 to 100.0)	60.0 (14.7 to 94.7)	100.0 (29.2 to 100.0)
Nodal (Positive Agreement)	50.0 (6.8 to 93.2)	0.0 (0.0 to 97.5)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Nodal (Overall agreement)	50.0 (6.8 to 93.2)	0.0 (0.0 to 84.2)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Skeletal (Positive Agreement)	100.0 (39.8 to 100.0)	100.0 (15.8 to 100.0)	999 (999 to 999)	999 (999 to 999)
Skeletal (Overall agreement)	100.0 (39.8 to 100.0)	100.0 (15.8 to 100.0)	999 (999 to 999)	999 (999 to 999)
Skin/Superficial (Positive Agreement)	100.0 (15.8 to 100.0)	999 (999 to 999)	0.0 (0.0 to 97.5)	999 (999 to 999)
Skin/Superficial (Overall agreement)	100.0 (15.8 to 100.0)	999 (999 to 999)	0.0 (0.0 to 97.5)	999 (999 to 999)
Soft Tissue/Visceral (Positive Agreement)	100.0 (39.8 to 100.0)	100.0 (39.8 to 100.0)	40.0 (5.3 to 85.3)	100.0 (29.2 to 100.0)
Soft Tissue/Visceral (Overall agreement)	100.0 (39.8 to 100.0)	100.0 (39.8 to 100.0)	40.0 (5.3 to 85.3)	100.0 (29.2 to 100.0)

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Percent agreement				
number (confidence interval 95%)				
Overall (Positive Agreement)	100.0 (2.5 to 100.0)			
Overall (Overall Agreement)	100.0 (2.5 to 100.0)			
Nodal (Positive Agreement)	0.0 (0.0 to 97.5)			
Nodal (Overall agreement)	0.0 (0.0 to 97.5)			
Skeletal (Positive Agreement)	999 (999 to 999)			
Skeletal (Overall agreement)	999 (999 to 999)			
Skin/Superficial (Positive Agreement)	999 (999 to 999)			
Skin/Superficial (Overall agreement)	999 (999 to 999)			
Soft Tissue/Visceral (Positive Agreement)	100.0 (2.5 to 100.0)			
Soft Tissue/Visceral (Overall agreement)	100.0 (2.5 to 100.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Organ-level analyses of Diagnostics by [68Ga]-NeoBOMB1 compared to histological evidence

End point title	Organ-level analyses of Diagnostics by [68Ga]-NeoBOMB1 compared to histological evidence
-----------------	--

End point description:

The diagnostic performance of [68Ga]-NeoBOMB1 to GRPR overexpressing malignancies (lesions) was to be compared with cytology and/or histopathology findings from archival and/or recent biopsy specimens. Since the biopsy was performed on 1 lesion (collected either in primary or in metastatic tumors), a direct link may not be possible in case of multiple lesions per organ identified on [68Ga]-NeoBOMB1-PET. In this event, the determination of positive versus negative lesions on [68Ga]-NeoBOMB1-PET was done at organ level, i.e., if any lesion is positive in that organ, then the organ was to be considered positive. The sensitivity was to be calculated as follows: Sensitivity = 100% x True positive / (True positive + False negative).

End point type	Secondary
----------------	-----------

End point timeframe:

Biopsy specimen collected within 6 months prior to study entry up to [68Ga]-NeoBOMB1 PET imaging acquired at Day 1

End point values	Breast	Prostate	Colorectal	Non-Small Cell Lung Cancer (NSCLC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	5	3
Units: Percent agreement				
number (confidence interval 95%)	80.0 (28.4 to 99.5)	100.0 (47.8 to 100.0)	20.0 (0.5 to 71.6)	100.0 (29.2 to 100.0)

End point values	Small-Cell Lung Cancer (SCLC)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Percent agreement				
number (confidence interval 95%)	0.0 (0.0 to 97.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Effective whole-body dose

End point title	Dosimetry Group: Effective whole-body dose ^[13]
-----------------	--

End point description:

The effective radiation dose was to be summarized with descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: mSv/MBq				
number (not applicable)				
Participant 1	0.0203			
Participant 2	0.0151			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: half-life of [68Ga]-NeoBOMB1 in blood ($T^{1/2}$)

End point title	Dosimetry Group: half-life of [68Ga]-NeoBOMB1 in blood ($T^{1/2}$) ^[14]
-----------------	--

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. The half-lives of distribution ($T^{1/2}$ alpha) and elimination phases ($T^{1/2}$ beta) were to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: min				
number (not applicable)				
Participant 1 - T ^{1/2} alpha	7.39			
Participant 1 - T ^{1/2} beta	40.35			
Participant 2- T ^{1/2} alpha	1.73			
Participant 2- T ^{1/2} beta	32.61			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Time of maximum observed drug concentration occurrence (Tmax)

End point title	Dosimetry Group: Time of maximum observed drug concentration occurrence (Tmax) ^[15]
-----------------	--

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. Tmax was to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: min				
number (not applicable)				
Participant 1	5.78			
Participant 2	5.73			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Observed maximum plasma concentration (Cmax)

End point title	Dosimetry Group: Observed maximum plasma concentration (Cmax) ^[16]
-----------------	---

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the

dosimetry group. Cmax was to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: kBq/cc				
number (not applicable)				
Participant 1	15.95			
Participant 2	31.31			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t))

End point title	Dosimetry Group: Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t)) ^[17]
-----------------	--

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. AUC(0-t) was to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: MBq-s/cc				
number (not applicable)				
Participant 1	40.67			
Participant 2	44.85			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: AUC(0-t) divided by the dose administered (AUC(0-t)/D)

End point title	Dosimetry Group: AUC(0-t) divided by the dose administered (AUC(0-t)/D) ^[18]
-----------------	---

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. AUC(0-t)/D was to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: s/cc				
number (not applicable)				
Participant 1	0.2101			
Participant 2	0.2301			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf)

End point title	Dosimetry Group: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) ^[19]
-----------------	---

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. AUC(0-inf) was to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: MBq-s/cc				
number (not applicable)				
Participant 1	44.49			
Participant 2	70.21			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Total systemic clearance for intravenous administration (CL)

End point title	Dosimetry Group: Total systemic clearance for intravenous administration (CL) ^[20]
-----------------	---

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. CL was to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: cc/s				
number (not applicable)				
Participant 1	43.50			
Participant 2	2.78			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Urinary excretion of [68Ga]-NeoBOMB1 (Vd)

End point title	Dosimetry Group: Urinary excretion of [68Ga]-NeoBOMB1
-----------------	---

End point description:

Urine samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. Vd was to be listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: Liter (L)				
arithmetic mean (standard deviation)	999 (± 999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Dosimetry Group: Absorbed dose in target organs

End point title	Dosimetry Group: Absorbed dose in target organs ^[22]
-----------------	---

End point description:

The absorbed dose in target organs and the effective radiation dose were to be summarized with descriptive statistics. Lesion number were assigned by dosimetry expert.

End point type	Secondary
----------------	-----------

End point timeframe:

[68Ga]-NeoBOMB1 PET imaging acquired at Day 1

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group.

End point values	Breast			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: mGy/MBq				
number (not applicable)				
Participant 1-Alveolar interstitial (Lungs)	0.0359			
Participant 1-Bone Marrow	0.0118			
Participant 1-Heart	0.0361			
Participant 1-Kidneys	0.0467			
Participant 1-Liver	0.0670			
Participant 1-Pancreas	0.3620			
Participant 1-Spleen	0.0221			
Participant 1-Urinary bladder wall	0.0683			
Participant 2-Alveolar interstitial (Lungs)	0.0241			
Participant 2-Bone Marrow	0.0064			
Participant 2-Heart	0.0158			
Participant 2-Kidneys	0.0339			

Participant 2-Liver	0.0450			
Participant 2-Pancreas	0.2270			
Participant 2-Spleen	0.0189			
Participant 2-Urinary bladder wall	0.1010			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events (AEs) were collected from informed consent signature through study completion (Day 14).

Adverse event reporting additional description:

Any sign or symptom that occurs after written informed consent provided. For TEAE from first dosing (single administration, Day 1) up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the patient was lost to follow-up or withdrew consent.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.1

Reporting groups

Reporting group title	Breast
-----------------------	--------

Reporting group description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Reporting group title	Prostate
-----------------------	----------

Reporting group description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Reporting group title	Colorectal
-----------------------	------------

Reporting group description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Reporting group title	Non-Small Cell Lung Cancer (NSCLC)
-----------------------	------------------------------------

Reporting group description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Reporting group title	Small-Cell Lung Cancer (SCLC)
-----------------------	-------------------------------

Reporting group description:

All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].

Serious adverse events	Breast	Prostate	Colorectal
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Blood and lymphatic system disorders			
Leukopenia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Non-Small Cell Lung Cancer (NSCLC)	Small-Cell Lung Cancer (SCLC)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	1 / 1 (100.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 1 (100.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 1 (100.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Breast	Prostate	Colorectal
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	3 / 5 (60.00%)
Investigations			
Blood cholinesterase decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0
Blood urea decreased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1
Injury, poisoning and procedural complications Post procedural constipation subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1
Procedural pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1
Vascular disorders Deep vein thrombosis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1
Hypertension subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1
Nervous system disorders Paralysis recurrent laryngeal nerve subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0	0 / 5 (0.00%) 0
Blood and lymphatic system disorders Anaemia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hyperfibrinogenaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperparathyroidism			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Hyperalbuminaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Hypochloraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Non-Small Cell Lung Cancer (NSCLC)	Small-Cell Lung Cancer (SCLC)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	1 / 1 (100.00%)	
Investigations			
Blood cholinesterase decreased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Blood lactate dehydrogenase increased			

subjects affected / exposed	1 / 3 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Blood urea decreased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 1 (100.00%)	
occurrences (all)	0	1	
C-reactive protein increased			
subjects affected / exposed	1 / 3 (33.33%)	1 / 1 (100.00%)	
occurrences (all)	1	1	
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 1 (100.00%)	
occurrences (all)	0	1	
Injury, poisoning and procedural complications			
Post procedural constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Procedural pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Nervous system disorders			
Paralysis recurrent laryngeal nerve			
subjects affected / exposed	1 / 3 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 1 (100.00%)	
occurrences (all)	0	1	
Hyperfibrinogenaemia			
subjects affected / exposed	1 / 3 (33.33%)	1 / 1 (100.00%)	
occurrences (all)	1	1	

Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0	
Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 1 (100.00%) 1	
Endocrine disorders Hyperparathyroidism subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 1 (100.00%) 1	
Metabolism and nutrition disorders Hyperalbuminaemia subjects affected / exposed occurrences (all) Hypochloraemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0	0 / 1 (0.00%) 0 1 / 1 (100.00%) 1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 November 2017	Amendment 1: Remove reference to a specific commercially available generator for IP reconstitution
14 February 2018	Amendment 2: 1) Update with available information on IP related to safety and dosimetry, 2) Revision of the schedule of assessments, 3) Clarifications on patients assignments in dosimetry or non-dosimetry group, 4) Clarification of the optional status of the routine clinical follow-up, 5) Clarification about allowed concomitant medication, 6) Update on references to ICH E6 and declaration of Helsinki.
05 July 2018	Amendment 3: Deletion of the reference to patients presenting relapsed or refractory metastatic cancer for both dosimetry and non-dosimetry groups to allow inclusion of patients at any stage of the disease.
06 August 2018	Amendment 4 (country specific to France): Reference to patients presenting metastatic cancer, relapsed or refractory, added for dosimetry group

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Recruitment was stopped before the target sample size was achieved..

Notes: